We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+10.82%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
+$313M
(+14%)
Cap. Flow
+$193M
Cap. Flow
% of AUM
7.73%
Top 10 Holdings %
Top 10 Hldgs %
67.82%
Holding
55
New
8
Increased
16
Reduced
5
Closed
6
Avg Time Held
1.5
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jade Biosciences
JBIO
|
+$60.3M |
| 2 |
Zai Lab
ZLAB
|
+$31.5M |
| 3 |
Aura Biosciences
AURA
|
+$29.8M |
| 4 |
Evolus
EOLS
|
+$24.9M |
| 5 |
Cytokinetics
CYTK
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rhythm Pharmaceuticals
RYTM
|
+$36M |
| 2 |
Soleno Therapeutics
SLNO
|
+$35.7M |
| 3 |
Merus
MRUS
|
+$15.7M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$7.81M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
+$7.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.84% |
| 2 | Miscellaneous | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$5.35B
| $346M | 13.83% |
6,795,121
| – | – |
2022 Q1
13 quarters
|
|
|
VRNA
2
DELISTED
Verona Pharma
VRNA
| $320M | 12.8% |
3,383,950
-73,900
| -2% | -$5.47M |
2022 Q3
11 quarters
|
|
3
NewAmsterdam Pharma
NAMS
$2.46B
| $301M | 12.03% |
16,607,074
+490,656
| +3% | +$8.95M |
2022 Q4
10 quarters
|
|
4
BridgeBio Pharma
BBIO
$13.1B
| $164M | 6.56% |
3,800,457
| – | – |
2023 Q1
9 quarters
|
|
5
Arcutis Biotherapeutics
ARQT
$3.66B
| $138M | 5.54% |
9,874,511
+1,089,227
| +12% | +$15.3M |
2022 Q1
13 quarters
|
|
6
Phathom Pharmaceuticals
PHAT
$607M
| $120M | 4.78% |
12,466,489
+2,357,210
| +23% | +$13M |
2022 Q1
13 quarters
|
|
7
Krystal Biotech
KRYS
$9.77B
| $94.6M | 3.78% |
688,460
| – | – |
2022 Q1
13 quarters
|
|
8
Disc Medicine
IRON
$2.17B
| $87.6M | 3.5% |
1,654,834
-100,000
| -6% | -$4.7M |
2023 Q2
8 quarters
|
|
9
MBX Biosciences
MBX
$2.44B
| $68.3M | 2.73% |
5,985,347
| – | – |
2024 Q3
3 quarters
|
|
10
Tarsus Pharmaceuticals
TARS
$3.32B
| $56.6M | 2.26% |
1,397,527
| – | – |
2022 Q1
13 quarters
|
|
11
Trevi Therapeutics
TRVI
$1.73B
| $56.1M | 2.24% |
10,259,409
| – | – |
2022 Q2
12 quarters
|
|
12
Maze Therapeutics
MAZE
$1.53B
| $56M | 2.24% |
4,567,275
+438,274
| +11% | +$4.56M |
2025 Q1
1 quarter
|
|
13
DELISTED
KalVista Pharmaceuticals
KALV
| $55.3M | 2.21% |
4,887,867
| – | – |
2022 Q1
13 quarters
|
|
|
14
Zai Lab
ZLAB
$2.64B
| $45.7M | 1.83% |
1,308,138
+958,138
| +274% | +$31.5M |
2025 Q1
1 quarter
|
|
15
Agios Pharmaceuticals
AGIO
$1.93B
| $42.6M | 1.7% |
1,279,754
+209,900
| +20% | +$6.36M |
2023 Q3
7 quarters
|
|
16
Revolution Medicines
RVMD
$40.6B
| $36.7M | 1.47% |
997,455
| – | – |
2023 Q1
9 quarters
|
|
17
Ultragenyx Pharmaceutical
RARE
$1.5B
| $35.8M | 1.43% |
983,715
+325,000
| +49% | +$11.7M |
2024 Q2
4 quarters
|
|
|
18
Aura Biosciences
AURA
$657M
| $31.9M | 1.28% |
+5,100,000
| New | +$29.8M |
2025 Q2
0 quarters
|
|
19
Erasca
ERAS
$5.2B
| $28.9M | 1.15% |
22,729,436
+153,585
| +0.7% | +$206K |
2024 Q2
4 quarters
|
|
20
Alkermes
ALKS
$6.73B
| $28.6M | 1.14% |
1,000,647
+399,518
| +66% | +$11.9M |
2024 Q3
3 quarters
|
|
21
Savara
SVRA
$974M
| $26.1M | 1.05% |
11,462,301
| – | – |
2023 Q3
7 quarters
|
|
22
Mereo BioPharma
MREO
$49.4M
| $25.6M | 1.02% |
9,440,112
+1,620,249
| +21% | +$3.91M |
2024 Q2
4 quarters
|
|
23
Ascendis Pharma A/S
ASND
$14.9B
| $23M | 0.92% |
133,333
| – | – |
2024 Q3
3 quarters
|
|
|
24
Evolus
EOLS
$500M
| $22.4M | 0.9% |
+2,435,550
| New | +$24.9M |
2025 Q2
0 quarters
|
|
25
DELISTED
HilleVax
HLVX
| $21.1M | 0.84% |
10,617,062
| – | – |
2022 Q2
12 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q2 2025 Portfolio in Review
As of Q2 2025, Frazier Life Sciences Management held 55 positions worth $2.5B, up 14% from $2.19B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Frazier Life Sciences Management deployed $193M of net new capital in Q2 2025, opening 8 new positions and adding to 16 existing holdings. Its largest new stake was Jade Biosciences: 1,772,116 shares worth $17.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Verona Pharma, an estimated $5.47M trimmed.
- Frazier Life Sciences Management's largest Q2 2025 buy was Jade Biosciences: 1,772,116 shares worth $17.7M.
- Frazier Life Sciences Management added most to Zai Lab in Q2 2025, an estimated $31.5M increase.
- Frazier Life Sciences Management's biggest Q2 2025 reduction was Verona Pharma, cutting an estimated $5.47M.
- Frazier Life Sciences Management fully exited Rhythm Pharmaceuticals in Q2 2025, selling an estimated $36M.
- Frazier Life Sciences Management's ten largest holdings make up 68% of its $2.5B portfolio in Q2 2025.
- Frazier Life Sciences Management opened 8 new positions and closed 6 in Q2 2025.
- Frazier Life Sciences Management's portfolio value rose 14% quarter-over-quarter to $2.5B.
Based on Frazier Life Sciences Management's 13F filing for Q2 2025, filed 14 Aug 2025.